Literature DB >> 19281453

Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells.

Eric Sulpice1, Shunli Ding, Béatrice Muscatelli-Groux, Mathieu Bergé, Zhong Chao Han, Jean Plouet, Gérard Tobelem, Tatyana Merkulova-Rainon.   

Abstract

BACKGROUND INFORMATION: Endothelial cells play a major role in angiogenesis, the process by which new blood vessels arise from a pre-existing vascular bed. VEGF-A (vascular endothelial growth factor-A) is a key regulator of angiogenesis during both development and in adults. HGF (hepatocyte growth factor) is a pleiotropic cytokine that may promote VEGF-A-driven angiogenesis, although the signalling mechanisms underlying this co-operation are not completely understood.
RESULTS: We analysed the effects of the combination of VEGF-A and HGF on the activation of VEGFR-2 (VEGF receptor-2) and c-met receptors, and on the stimulation of downstream signalling pathways in endothelial cells. We found that VEGFR-2 and c-met do not physically associate and do not transphosphorylate each other, suggesting that co-operation involves signalling events more distal from receptor activation. We demonstrate that the VEGF isoform VEGF-A(165) and HGF stimulate a similar set of MAPKs (mitogen-activated protein kinases), although the kinetics and strengths of the activation differ depending on the growth factor and pathway. An enhanced activation of the signalling was observed when endothelial cells were stimulated by the combination of VEGF-A(165) and HGF. Moreover, the combination of VEGF-A and HGF results in a statistically significant synergistic activation of ERK1/2 (extracellular-signal-regulated kinase 1/2) and p38 kinases. We demonstrated that VEGF-A(165) and HGF activate FAK (focal adhesion kinase) with different kinetics and stimulate the recruitment of phosphorylated FAK to different subsets of focal adhesions. VEGF-A(165) and HGF regulate distinct morphogenic aspects of the cytoskeletal remodelling that are associated with the preferential activation of Rho or Rac respectively, and induce structurally distinct vascular-like patterns in vitro in a Rho- or Rac-dependent manner.
CONCLUSIONS: Under angiogenic conditions, combining VEGF-A with HGF can promote neovascularization by enhancing intracellular signalling and allowing more finely regulated control of the signalling molecules involved in the regulation of the cytoskeleton and cellular migration and morphogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19281453     DOI: 10.1042/BC20080221

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  64 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.

Authors:  L Zazzeroni; G Lanzoni; G Pasquinelli; C Ricordi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2017-09-29

3.  A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.

Authors:  Lipika Goyal; Hui Zheng; Matthew B Yurgelun; Thomas A Abrams; Jill N Allen; James M Cleary; Michelle Knowles; Eileen Regan; Amanda Reardon; Anna Khachatryan; Rakesh K Jain; Valentina Nardi; Darrell R Borger; Dan G Duda; Andrew X Zhu
Journal:  Cancer       Date:  2017-02-13       Impact factor: 6.860

4.  Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects.

Authors:  Hassan K Awada; Noah R Johnson; Yadong Wang
Journal:  Macromol Biosci       Date:  2014-01-23       Impact factor: 4.979

5.  Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.

Authors:  Erika Guise; Jason E Engel; Maxx L Williams; Fakhri Mahdi; Gene L Bidwell; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

Review 6.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

7.  Persistent Hyperactivation of Endothelial Cells in Patients with Alcoholic Hepatitis.

Authors:  Ying Xia; Jing Yang; Arun J Sanyal; Vijay H Shah; Naga P Chalasani; Qigui Yu; Xiaoqun Zheng; Wei Li
Journal:  Alcohol Clin Exp Res       Date:  2020-04-21       Impact factor: 3.455

8.  Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling.

Authors:  Boleslaw K Winiarski; Katarzyna I Wolanska; Srijana Rai; Tahanver Ahmed; Nigel Acheson; Nicholas J Gutowski; Jacqueline L Whatmore
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

9.  Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

Authors:  David Tai; Donald Poon
Journal:  J Oncol       Date:  2010-08-24       Impact factor: 4.375

10.  Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene.

Authors:  Mehrnoosh Saghizadeh; Andrei A Kramerov; Fu-Shin X Yu; Maria G Castro; Alexander V Ljubimov
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.